This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

HELMUTH RÖSLER, MD
Bern, Switzerland

Arch Otolaryngol Head Neck Surg. 1987;113(7):778.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—In his article about therapy for differentiated thyroid cancer, Dunn describes the benefits of treating patients who have differentiated thyroid carcinomas with exogenous thyroid hormones and compares this treatment with radioiodine therapy. He maintains that "the value and optimal application of this [radioiodine] therapy remain controversial" and that "a satisfactory controlled investigation still needs to be done." On the other hand, he explains the effect of exogenous thyroid hormones as being due to a reduction in the level of thyrotropin, which "may be an important growth factor" in these tumors.

To my knowledge, there is not a single patient described in the literature in whom a primary tumor or a histologically proved metastasis of a differentiated thyroid carcinoma regressed in size or even ceased to grow under treatment with thyroid hormones alone. The explanation given by the author for those well-differentiated cancers that "hypersecrete thyroid hormone and . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?